TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19704058

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cetuximab (D + C)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Bortezomib (D + B)
Number of subjects: 59
Study: 16495192

Group type: EXPERIMENTAL
Intervention: Scalp electroacupuncture with Madopar
Number of subjects: 30

Group type: COMPARATOR
Intervention: Madopar only (Control)
Number of subjects: 30
Study: 14653129

Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) therapy (4 U per day for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: human albumin (10 g every other day for 3 times)
Number of subjects: 15
Study: 10827559

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9124393

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus infusion over 5 min, followed by 50 µg x kg(‐1) x min(‐1) over 120 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-arginine (17 mg x kg(‐1) x min(‐1) over 30 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 8
Study: 8310886

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg post-evening meal (pem)
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Ranitidine and cimetidine
Number of subjects: 1672
Study: 3728026

Group type: EXPERIMENTAL
Intervention: Attest No. 1262 BI (ABI)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Swedish BI (SBI)
Number of subjects: 720
Study: 30477864

Group type: EXPERIMENTAL
Intervention: Crocetin 7.5 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26653113

Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (3-180 mg single dose)
Number of subjects: 65

Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 10 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 21 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25516360

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/d for 3 months) with psychosocial intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Psychosocial intervention without donepezil
Number of subjects: 32
Study: 22813677

Group type: EXPERIMENTAL
Intervention: Traffic Light
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Traffic Light+
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Facts Up Front
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Facts Up Front+
Number of subjects: 703

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 703
Study: 20337976

Group type: EXPERIMENTAL
Intervention: Hydrolysed rice protein formula (HRPF)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Extensively hydrolysed cow's milk formula (EHF)
Number of subjects: 92
Study: 18724153

Group type: EXPERIMENTAL
Intervention: Single rotational flap (group A, 19 eyes)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Double sliding flaps (group B, 15 eyes)
Number of subjects: 33
Study: 16382306

Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus) subcutaneously at a dosage equal to the average of insulin/day administered in the preceding days of AN
Number of subjects: 21
Study: 15189606

Group type: EXPERIMENTAL
Intervention: Task instructions that fit participants' implicit theory (fun or importance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task instructions that did not fit participants' implicit theory (fun or importance)
Number of subjects: 0
Study: 12593425

Group type: EXPERIMENTAL
Intervention: Tc‐99m MAA injection in cirrhosis patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control subjects (11 subjects)
Number of subjects: 3
Study: 9650539

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 11 mg/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 22 mg/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 44 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Baseline smoking rate
Number of subjects: 70
Study: 8589208

Group type: EXPERIMENTAL
Intervention: Argatroban (2.5 mg/h for the first 48 hours, then 10 mg infused over 3 hours twice a day on days 3-7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2572899

Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid (400 mg) and rifampicin (600 mg)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Twice-weekly treatment with isoniazid (900 mg) and rifampicin (600 mg)
Number of subjects: 667
Study: 4824312

Group type: EXPERIMENTAL
Intervention: Recovery intervals of 1 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recovery intervals of 2 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recovery intervals of 4 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recovery intervals of 6 min
Number of subjects: 24
Study: 31884429

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 53
Study: 28739536

Group type: EXPERIMENTAL
Intervention: Time2bHealthy online healthy lifestyle program for parents (11-week program)
Number of subjects: 0
Study: 26525004

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse in non-smokers (G1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Selective enamel etching in non-smokers (G2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse in smokers (G3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Selective enamel etching in smokers (G4)
Number of subjects: 38
Study: 23438094

Group type: EXPERIMENTAL
Intervention: Unipolar cautery alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bipolar tissue sealant device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (estimated blood loss)
Number of subjects: 60
Study: 21600066

Group type: EXPERIMENTAL
Intervention: eBaViR (Wii Balance Board-based system), 20 one-hour sessions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 17
Study: 19508250

Group type: EXPERIMENTAL
Intervention: SRP&DOXY (scaling and root planing with 14% doxycycline gel applied subgingivally)
Number of subjects: 39

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 39
Study: 16536148

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with rubber dam isolation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide without rubber dam isolation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adhesive resin with rubber dam isolation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adhesive resin without rubber dam isolation
Number of subjects: 40
Study: 15120713

Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 36
Study: 10709793

Group type: EXPERIMENTAL
Intervention: Teacher training programs (65 in-service programs)
Number of subjects: 500
Study: 9108785

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined placebo and lovastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment groups
Number of subjects: 0
Study: 8185726

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (600 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (nonrunning control group)
Number of subjects: 100
Study: 30067555

Group type: EXPERIMENTAL
Intervention: PNF lower-leg taping with treadmill training (PNFLT-TT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 27
Study: 27271007

Group type: EXPERIMENTAL
Intervention: Design optimal for heterogeneous costs and homogeneous variances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced design
Number of subjects: 0
Study: 23412624

Group type: EXPERIMENTAL
Intervention: Hot Humid (HH) environment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hot Dry (HD) environment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Temperate (TEMP) environment
Number of subjects: 11
Study: 21910937

Group type: EXPERIMENTAL
Intervention: Daily rTMS (5 days/week for 4 weeks, 20 treatments in total)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Spaced rTMS (3 days/week for 6 weeks, 18 treatments in total)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (Daily and Spaced rTMS)
Number of subjects: 77
Study: 20592439

Group type: EXPERIMENTAL
Intervention: Feedback to website administrators about the quality of information on their website
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (websites that did not receive feedback)
Number of subjects: 52
Study: 18757164

Group type: EXPERIMENTAL
Intervention: HPV triage
Number of subjects: 106

Group type: COMPARATOR
Intervention: Repeat Pap testing
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 106
Study: 16463694

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in synovial fluid of rheumatoid arthritis patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in synovial fluid of osteoarthritis patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in serum of all investigated groups
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Specific activity of Hex in synovial fluid of rheumatoid arthritis patients
Number of subjects: 54
Study: 12468134

Group type: EXPERIMENTAL
Intervention: Estradot transdermal oestrogen patch (50 microg/day)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Menorest transdermal oestrogen patch (50 microg/day)
Number of subjects: 208
Study: 10479159

Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 300 mg daily for 7 days (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 500 mg daily for 3 days (Group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 1 dose of 500 mg (Group C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chloroquine only (Group D)
Number of subjects: 44
Study: 8568114

Group type: EXPERIMENTAL
Intervention: 40% carbohydrate diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: 55% carbohydrate diet
Number of subjects: 25
Study: 1720759

Group type: EXPERIMENTAL
Intervention: Alternating weekly chemotherapy regimen including Doxorubicin, vincristine, cyclophosphamide, bleomycin, intrathecal methotrexate and cytarabine, Methotrexate with leucovorin rescue, Ifosfamide with mesna, etoposide, and intrathecal methotrexate and cytarabine
Number of subjects: 75

Group type: COMPARATOR
Intervention: One additional cycle or three monthly CHOP (consolidation treatment)
Number of subjects: 75
Study: 6819029

Group type: EXPERIMENTAL
Intervention: Protein energy supplement (energy and vitamins with 5-10% of energy from milk protein)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vitamins only (a multivitamin sachet daily containing vitamins A, B, C, and D)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Energy (42-125 MJ from carbohydrate, plus vitamins)
Number of subjects: 128
Study: 31289956

Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Disease Control Rate (DCR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Early Tumor Shrinkage (ETS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Progression-Free Survival (PFS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Overall Response Rate (ORR)
Number of subjects: 12
Study: 29759808

Group type: EXPERIMENTAL
Intervention: Clinical nursing pathway (CNP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 118
Study: 26931763

Group type: EXPERIMENTAL
Intervention: On-site urine drug screening tests (OS-UDS) with training for GPs and supply of tests at medical offices.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Usual care (standard medical strategy for assessing drug use).
Number of subjects: 1
Study: 24375296

Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Number of subjects: 267

Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 267
Study: 22310400

Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKA
Number of subjects: 82

Group type: COMPARATOR
Intervention: Mechanically aligned TKA
Number of subjects: 82
Study: 20563294

Group type: EXPERIMENTAL
Intervention: Aggressive treatment targets for LDL-C ≤70 mg/dL and systolic BP ≤115 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment targets for LDL-C ≤100 mg/dL and systolic BP ≤130 mmHg
Number of subjects: 0
Study: 17069666

Group type: EXPERIMENTAL
Intervention: GHQ-28 Farsi version
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: GHQ-15 (derived short form)
Number of subjects: 204
Study: 15149896

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SUPPORT)
Number of subjects: 57
Study: 12102278

Group type: EXPERIMENTAL
Intervention: Weekly dose of 100 mg of leflunomide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional dose of leflunomide
Number of subjects: 16
Study: 9695721

Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg total intravenous dose) in addition to baseline dual immunosuppression (cyclosporine and steroids)
Number of subjects: 0
Study: 7907646

Group type: EXPERIMENTAL
Intervention: Delayed-type hypersensitivity (DTH) testing
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Reactive patients (response > 2 mm to any antigens)
Number of subjects: 336
Study: 2673516

Group type: EXPERIMENTAL
Intervention: Fixed combination of semisynthetic human insulin (Novolin) providing a 70:30 ratio of NPH to regular insulin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Variable ratio of semisynthetic human insulin, regular and NPH (control group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both groups (fixed-ratio and control)
Number of subjects: 72
Study: 1151293

Group type: EXPERIMENTAL
Intervention: nurse‐proctocol treatment plan
Number of subjects: 146

Group type: COMPARATOR
Intervention: physician treatment plan
Number of subjects: 146
Study: 31520838

Group type: EXPERIMENTAL
Intervention: Mouse allergen reduction
Number of subjects: 0
Study: 30395904

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily during and up to 3 months after RT
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28891544

Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Epi-Jet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Loss of Resistance (LOR)
Number of subjects: 240
Study: 25724455

Group type: EXPERIMENTAL
Intervention: Infliximab dosing based on therapeutic drug monitoring (TCs)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Infliximab dosing based on clinical features
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Dose escalation to reach TCs of 3-7 μg/mL
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Dose reduction for TCs >7 μg/mL
Number of subjects: 263
Study: 24382088

Group type: EXPERIMENTAL
Intervention: High intensity treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low intensity treatment
Number of subjects: 100
Study: 21992849

Group type: EXPERIMENTAL
Intervention: Low-dose human atrial natriuretic peptide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19535720

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 230

Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 230
Study: 17470516

Group type: EXPERIMENTAL
Intervention: Cycling for 60 min at 65% of maximal heart rate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting (control)
Number of subjects: 12
Study: 15894969

Group type: EXPERIMENTAL
Intervention: Standard CR (33 sessions for 3 months)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Distributed CR (33 sessions for 12 months)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard CR
Number of subjects: 392

Group type: COMPARATOR
Intervention: Distributed CR
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Standard CR and Distributed CR
Number of subjects: 392
Study: 12160277

Group type: EXPERIMENTAL
Intervention: Non-Hodgkin lymphoma (NHL)
Number of subjects: 165
Study: 10378911

Group type: EXPERIMENTAL
Intervention: Initial running speed of 3.0 km x h(‐1) below the RS‐LT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Initial running speed of 0.5 km x h(‐1) below the RS‐LT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: RS‐LT
Number of subjects: 8
Study: 7783109

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Enalapril (10-40 mg once daily)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Amlodipine (continued for 2 years)
Number of subjects: 461
Study: 2083405

Group type: EXPERIMENTAL
Intervention: Allergen-antibody complexes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carrier buffer (control)
Number of subjects: 30
Study: 395631

Group type: EXPERIMENTAL
Intervention: jejunoileostomy with a 3:1 jejunoileal ratio
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: jejunoileostomy with a 1:3 jejunoileal ratio
Number of subjects: 95

Group type: COMPARATOR
Intervention: non‐operative management
Number of subjects: 95
Study: 31156168

Group type: EXPERIMENTAL
Intervention: Recruitment strategies and facilitators
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Embedding research into routine patient care
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Collaboration with services to identify eligible patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Training and engaging trial staff
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Providing clear and concise study information to patients
Number of subjects: 17
Study: 27965049

Group type: EXPERIMENTAL
Intervention: Rong‐Yang‐Jyh‐Gan‐Tang (RYJGT) 15g/day for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rong‐Yang‐Jyh‐Gan‐Tang (RYJGT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25992812

Group type: EXPERIMENTAL
Intervention: 18 mm shaft diameter esophageal stent
Number of subjects: 100

Group type: COMPARATOR
Intervention: 23 mm shaft diameter esophageal stent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Small-diameter stent (18 mm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Large-diameter stent (23 mm)
Number of subjects: 100
Study: 23869828

Group type: EXPERIMENTAL
Intervention: Pre-heated infusion solutions (colloids and crystalloids)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: General anaesthesia with actively heated mothers
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-heated mothers operated under subarachnoid anaesthesia
Number of subjects: 29
Study: 21803933

Group type: EXPERIMENTAL
Intervention: tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 14
Study: 19699854

Group type: EXPERIMENTAL
Intervention: SCH 530348 2.5 mg daily
Number of subjects: 27000

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 27000
Study: 16394051

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9
Number of subjects: 235
Study: 15492133

Group type: EXPERIMENTAL
Intervention: Thiorphan (30 nmol/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bradykinin (30 to 300 pmol/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (10 to 100 pmol/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2 to 8 mug/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10516738

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (starting with irbesartan 75 mg/HCTZ 12.5 mg once daily, titrated to irbesartan 150 mg/HCTZ 12.5 mg, then to irbesartan 300 mg/HCTZ 25 mg if necessary)
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy
Number of subjects: 1098
Study: 7854377

Group type: EXPERIMENTAL
Intervention: D allele of the ACE gene
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control group (no D allele)
Number of subjects: 1250
Study: 2371577

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with upper urinary tract infections
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract infections
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract symptoms and underlying diseases
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with lower urinary tract infections
Number of subjects: 57
Study: 7247360

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 200 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SMX-TMP) 800/160 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study: 31615781

Group type: EXPERIMENTAL
Intervention: Routine ultrasonography in the third trimester (two routine biometry scans at 28‐30 and 34‐36 weeks' gestation)
Number of subjects: 13046

Group type: COMPARATOR
Intervention: Usual care (serial fundal height measurements with clinically indicated ultrasonography)
Number of subjects: 13046
Study: 28744102

Group type: EXPERIMENTAL
Intervention: Generic alendronate sodium tablets (70 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fosamax® tablets (70 mg) - first dose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fosamax® tablets (70 mg) - second dose
Number of subjects: 36